Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has announced that it has secured funding of £2.4 million with investments from high-profile UK and US investors. Spirea will use the funds to initiate its pipeline of superior and differentiated ADCs in the treatment of solid tumours where there is a high unmet need.

Aramune Technologies has raised £800,000 of new equity funding to develop an industrial-scale process for manufacturing its first product.

Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised £2.2M in funding from existing investors ACF Investors, o2h Ventures, Meltwind Advisory, a number of returning angels and new investors and the US-based R42 Group. This brings the firm’s total amount of grant and equity funding to over £10M. 

Biotangents, a Scottish biotechnology business, has secured £2.2m of new funding made up from £1.6m from the UK Government’s Innovate UK innovation loans programme and a further £600k from a funding round lead by the investment syndicate Kelvin Capital and with Scottish Enterprise participation to support the development and roll-out of its ‘on farm’ rapid disease detection technology.

HBAN (Halo Business Angel Network) syndciates have led a €1.925M investment in Galway-based start-up, SymPhysis Medical. Angels from HBAN’s MedTech Syndicate, Irrus Investments and Boole Investment Syndicate invested a combined €925K in the company, which is developing a device that eases the discomfort and distress of fluid in the chest for cancer patients undergoing palliative care.

MitoRx Therapeutics secures investment from Science Angel Syndicate to develop its first-in-class therapeutics that target dysfunctional sulfide-signalling in mitochondria to halt the progress of degenerative diseases.

Science Angel Syndicate (SAS) was launched in September 2021 to supportinvestments into frontier scientific discoveries that impact society on a global scale. Leveraging their unique due diligence capabilities they have supported SAS investors to make an investment into MitoRx Therapeutics. 

52 North Health, a UK and US-based med-tech start-up, has raised £1 million in its first round of funding from leading UK and European specialist investors. The round was led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, with participation from Crista Galli Ventures, King’s Health Partners MedTech Innovations, Meltwind, Milltrust Ventures and a number of angels.

SETsquared Bristol member LatchAid, an award winning breastfeeding and early parenthood support innovator, has closed its seed funding round with an ultra-competitive £510k Innovate UK Innovation Loan, bringing total investments to £1m, as testament to its ground-breaking technology and user traction.

Biomedical startup Adapttech has raised £2.25 million from investors including Mercia Asset Management, ACF Investors, Wren Capital and Wealth Club. The company also announced the launch of the new INSIGHT Range, a family of products that make it faster and easier to fit lower-limb prostheses and improve patient outcomes.

Sano Genetics, co-founded by three University of Cambridge genomics postgraduates, has raised $11M in a Series A funding round led by MMC Ventures, with further funding from Episode 1, Seedcamp and several angel investors, including Paul Forster, a co-founder and former CEO of Indeed, Paul Wicks, former VP of innovation at PatientsLikeMe, and Margo Georgiadis, the former CEO of Ancestry.com.

Award-winning hybrid studio and digital fitness platform BLOK has  secured £3.75m in a funding round led by ACF Investors, with additional investment from Elcot  Capital and The Santon Group. The funding round also included investment from the UK  government’s Future Fund, Crowdcube and angel investor Rob Wirszycz, who will be joining the  business as Chairman.  

Tonic Health, a natural healthcare company that combines all-in-one vitamins, minerals and plants into a drink that fuels the immune system to help end unnecessary illness, has received investment from Henley Business Angels as part of a £463,000.funding round.